Kimberly-Clark Corp. (KMB)
Kimberly-Clark Corp. (KMB) is a leading multinational consumer goods company specializing in the production of personal care, hygiene, and health-related products. The company's offerings include well-known brands such as Kleenex, Huggies, and Scott, serving both retail consumers and commercial businesses worldwide. Founded in 1872, Kimberly-Clark has a long history of innovation in disposable paper products and emphasizes sustainability and social responsibility in its operations.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| October 2, 2025 | $1.26 | 2025-09-05 | 2025-09-05 |
| July 2, 2025 | $1.26 | 2025-06-06 | 2025-06-06 |
| April 2, 2025 | $1.26 | 2025-03-07 | 2025-03-07 |
| January 3, 2025 | $1.22 | 2024-12-06 | 2024-12-06 |
| October 2, 2024 | $1.22 | 2024-09-06 | 2024-09-06 |
Dividends Summary
- Kimberly-Clark Corp. has issued 88 dividend payments over the past 21 years
- The most recent dividend was paid 20 days ago, on October 2, 2025
- The highest dividend payed out to investors during this period was $1.26 per share
- The average dividend paid during this period was $0.84 per share.
Company News
Sarasin & Partners LLP added 963,978 shares of Kimberly-Clark, valued at $119.87 million, increasing its total stake to 2,048,544 shares. The position represents 2.47% of the fund's assets under management, placing it outside the top five holdings.
The global breathable films market is projected to grow from $19.80 billion in 2024 to $31.44 billion by 2034, with a CAGR of 5.95%. The market is driven by increasing demand in healthcare, hygiene, and packaging industries, with Asia Pacific expected to be the fastest-growing region.
Lululemon and Tesla were among the top 10 large-cap losers last week, with Lululemon shares plunging 16.2% after Q1 results and analyst downgrades, and Tesla dropping 14.8% partly due to Elon Musk's tensions with Trump.
During periods of heightened volatility, low-beta stocks can provide a valuable layer of defense and a more balanced risk profile. Northrop Grumman, Pfizer, and Kimberly-Clark have recently seen positive earnings estimate revisions, landing them in favorable Zacks Ranks.
Kimberly-Clark reported second quarter earnings that beat estimates by $0.25, but revenue fell short of the consensus estimate.
